CD19 and cancer: MRTX1133, via Fas ligand on CD8+ T cells activated Fas-mediated apoptosis of cancer cells and led to a significant increase in the number of CD3+ T cells, CD8+ T cells, and CD19+ cells, and a decrease in CD11b+ myeloid infiltration (25).